Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Mini-Review
You have accessRestricted Access

Control of Secondary Hyperparathyroidism by Vitamin D Receptor Agonists in Chronic Kidney Disease

Stuart M. Sprague and Daniel Coyne
CJASN March 2010, 5 (3) 512-518; DOI: https://doi.org/10.2215/CJN.03850609
Stuart M. Sprague
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Coyne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

Effective treatment options for managing secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) have advanced steadily since the early 1980s, from surgical removal of the parathyroid gland to pharmacologic intervention focused on reestablishing hormonal and mineral balances. In addition, earlier recognition of CKD via estimated GFR and educational efforts have led to advancements in diagnosis and treatment of elevated parathyroid hormone (PTH) and vitamin D deficiency. Clinical studies support the efficacy and safety of vitamin D receptor (VDR) agonists as effective treatments for SHPT. A number of considerations to ensure optimal SHPT control in CKD patients are apparent. VDR agonists effectively treat SHPT and vitamin D deficiency, but dosing needs to be optimized for each patient because the patient responds in an individualized manner to treatment to suppress and stabilize PTH levels. VDR agonist therapy should be continuous to ensure continued PTH suppression, coupled with strict monitoring of calcium and phosphorus to ensure compliance within target ranges. Awareness of the complex and beneficial effects of VDR agonists contributes to improved benefits in bone mineral disease and lower mortality risks.

Treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) has evolved over the last few decades, with a better understanding of the underlying pathophysiology and the development of advanced and safer medications. Management of SHPT remains a challenge because of the complex interrelationship of hormones, bone health, diet, and mineral balances within the body. Bone and mineral guidelines were recently updated by the Kidney Disease: Improving Global Outcomes (KDIGO) working group from the 2003 National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI), with the goal of providing guidance in managing CKD patients (1,2). At the time of the release of the 2003 guidelines, clinical studies in patients with moderate to severe CKD and SHPT showed that treatment with vitamin D receptor (VDR) agonists lowered elevated parathyroid hormone (PTH) levels but caused variable increases in serum calcium (Ca) and phosphorus (P) (3,4). Although the target ranges for PTH per each CKD stage have been updated in the new KDIGO guidelines to be more reflective of current trends, changes in Ca and P outside of normal levels are still viewed as potentially harmful by experts (2).

Observational data have shown a more complex and even contradictory relationship of Ca and P to mortality, challenging theories that any increase in these mineral ions increases risk to the patient (5,6). Observational studies have shown that low vitamin D (25-hydroxyvitamin D (25-D) and 1,25-dihydroxyvitamin D (1,25-D)) levels are associated with CKD progression (7) as well as increased risk of mortality beginning at stage 3 CKD (7,8). Administration of oral or injectable vitamin D and/or VDR agonists (e.g., calcitriol) in patients on dialysis or with stages 3 and 4 CKD has been correlated with improved survival in observational studies (8–11). Additional observational analyses have shown that treatment with paricalcitol, an analog of calcitriol with fewer calcemic and phosphatemic effects, is associated with enhanced survival in patients undergoing long-term hemodialysis compared with those who did not receive vitamin D analogs (12). Another study showed enhanced survival benefit of paricalcitol compared with calcitriol (13). Although use of these and other VDR agonists (Table 1) to treat low endogenous 1,25-D hormonal levels is hypothesized to account for clinical benefits that include improved survival, prospective randomized, controlled trials are necessary to validate these findings. On the basis of results from clinical studies and through the practical use of therapies to control elevated PTH, replete vitamin D levels, and treat bone mineral disease, a number of considerations when using VDR agonists have arisen that should be taken into account for providing optimal SHPT control in patients with CKD (Table 2).

View this table:
  • View inline
  • View popup
Table 1.

Vitamin D nomenclature

View this table:
  • View inline
  • View popup
Table 2.

VDR agonists and SHPT control

CKD, SHPT, and Vitamin D Deficiency

An estimated 16 million people in the United States have stage 3 or 4 CKD (eGFR 15–59 ml/min per 1.73 m2), with diabetes mellitus and hypertension as major underlying causes (14). Despite the high prevalence of CKD in the adult population, less than 20% of patients who have moderately decreased kidney function are aware of this impairment (15). A prospective, observational study of 1814 CKD patients with a recent historic eGFR of <60 ml/min per 1.73 m2 confirmed that 78% of patients had stage 3, 4, or 5 CKD with elevated PTH and significantly reduced 1,25-D levels (16). Rising PTH levels were inversely correlated with declining 1,25-D and 25-D levels; 1,25-D levels were approaching very low levels (<25 pg/ml) as eGFR measurements signified stage 3 CKD. eGFR continued to decline thereafter. These and other study findings substantiate a high incidence of SHPT and low endogenous vitamin D (25-D and/or 1,25-D) levels in CKD patients, supporting the KDIGO recommendations for early and continued measurement of these parameters throughout disease progression (2,9,16–19). These observations support the view that SHPT occurs early and, if left untreated, worsens over time. VDR agonist therapy for dialysis patients has been well documented; however, treatment options for patients with early stages of CKD are less established.

Vitamin D Deficiency and Treatment to Modulate SHPT in CKD Patients

There is ongoing debate regarding a clear definition for what is considered vitamin D (25-D and/or 1,25-D) deficiency. Vitamin D deficiency is usually defined as concentrations <10 ng/ml (25 nmol/L), whereas vitamin D insufficiency is defined as levels between 10 and 32 ng/mL (80 nmol/L). Vitamin D concentrations between 32 and 80 ng/mL (200 nmol/L) are generally considered sufficient (2). Vitamin D (25-D and/or 1,25-D) sufficiency is less well defined because numerous factors contribute to achieving adequate endogenous vitamin D levels, and the nomenclature for endogenous and exogenous vitamin D is very similar (Table 1). Because 1,25-D functions as a native hormone, providing complex, tissue-specific signaling throughout the body, it is a challenge to accurately measure the relative contribution of exogenously administered vitamin D with signaling that is occurring through autocrine/paracrine feedback loops (20). The interrelated effects between native and supplemented vitamin D are reiterated in a study examining the effects of exogenously administered 1,25D (i.e., calcitriol) in healthy volunteers and uremic patients. Gallieni et al. (21) showed that although dialysis patients have impaired uptake and metabolism of 25-D, treatment with calcitriol not only repleted serum 1,25-D levels but also increased the uptake of 25-D (as examined in monocytes). Thus, with exogenous 1,25-D administration, there are potential complementary benefits to both 1,25-D and 25-D in an effort to rebalance the hormonal system.

Treatment of Vitamin D Deficiency and SHPT in Patients with Stages 3 and 4 CKD

Deficiencies in 25-D and/or 1,25-D have been associated with an elevated risk of cardiovascular disease and mortality in the general population (22,23). Suboptimal levels of vitamin D contribute to the development of SHPT through reduced intestinal Ca absorption, increased PTH production, and parathyroid cell proliferation (24). Elevated PTH may also initiate increased Ca and P resorption from bone and promote vascular calcification (24,25). Despite elevation in PTH and reductions in endogenous vitamin D (i.e., 25-D and 1,25-D), serum Ca and P usually remain within normal physiologic range in stages 3 and 4 CKD (16,17).

Inactive forms of supplementary vitamin D, ergocalciferol (vitamin D2), and cholecalciferol (vitamin D3), significantly increase 25-D and 1,25-D levels in patients with stages 3 and 4 CKD and suppress, but do not normalize, PTH concentrations (26–28). Beginning with stage 4 CKD, the ability of vitamin D supplements to correct elevated PTH concentrations is significantly reduced compared with earlier stages of CKD (26,28). These supplements are generally considered ineffective for PTH suppression in usual doses in patients with stage 5 CKD (before or in those receiving dialysis), although they may prevent osteomalacia due to vitamin D deficiency and possibly have other benefits.

The biologically active VDR agonists calcitriol and paricalcitol, and the prohormone doxercalciferol, suppress PTH in a dose-related fashion independent of the stage of CKD. Placebo-controlled trials of these exogenously administered agents in patients with stages 3 and 4 CKD demonstrated that calcitriol and doxercalciferol elevated serum Ca, although doxercalciferol may have been less calcemic than calcitriol (3,29,30). Trials of paricalcitol showed significant and sustained control of PTH, with minimal alterations in Ca and P compared with placebo (30). Although the changes observed in Ca and P in these studies are consistent with animal data showing differences in the calcemic and phosphatemic effects of these agents (31,32), definitive claims of differences between compounds await randomized trials comparing these agents in patients with CKD stages 3 and 4. Markers of bone formation, such as bone-specific alkaline phosphatase, were also significantly reduced by VDR agonist treatment (3,29,30). Current KDIGO guidelines do not recommend bone mineral density measurements for CKD but do suggest that stages 3 to 5 CKD patients be measured for serum PTH or bone-specific alkaline phosphatase to predict for low or high bone turnover (2).

Treatment of SHPT in Dialysis Patients

In the late 1980s, intravenous (IV) calcitriol was recommended as an alternative therapy to either oral calcitriol or parathyroidectomy in dialysis patients with SHPT. Long-term intermittent infusions of IV calcitriol 1 to 2.5 μg thrice weekly for an average of 11.5 months in dialysis patients with concomitant osteitis fibrosa achieved significant reductions in PTH and alkaline phosphatase, and resulted in fewer episodes of hypercalcemia than experienced with prior therapy (33). In the late 1990s, investigators demonstrated that by lowering the level of PTH in hemodialysis patients, IV calcitriol 2 μg twice weekly not only attenuated the SHPT effects but also displayed cardioprotective effects (34). Interestingly, the increased use of calcitriol as a therapeutic intervention has been associated with a reduction in parathyroidectomy rates in the late 1990s to <1% and a shift in the treatment paradigm from a surgical intervention to pharmacologic management of SHPT (35).

Doxercalciferol (a prohormone that can be hepatically activated into a VDR agonist) was originally investigated as a treatment for osteoporosis (36) and later demonstrated its efficacy by reducing PTH in hemodialysis patients, albeit with elevations in serum Ca and P (37,38). Unfortunately, there have been no studies directly comparing doxercalciferol with other VDR agonists. Alphacalcidol (not approved for use in the United States) is 1α-hydroyvitamin D3, which is rapidly converted in the liver to 1,25-dihydroxy vitamin D3 (39). Vitamin-resistant disorders, such as renal bone disease, hypoparathyroidism, and pseudodeficiency rickets, which usually require large amounts of vitamin D, respond to physiologic doses of alphacalcidol. Alphacalcidol may cause hypercalcemia. In a randomized prospective phase III study, IV paricalcitol 0.04 to 0.24 μg (given for up to 32 weeks) showed similar or improved PTH suppression and fewer hypercalcemic episodes compared with IV calcitriol 0.01 to 0.06 μg (40).

Optimal PTH Suppression through Individualized Dosing and Continuous VDR Agonist Therapy

In 2003, KDOQI experts offered CKD stage-specific PTH target ranges; these targets lacked rigorous trial evidence and are no longer considered adequate for management of the individual patient (1). Bone biopsy series in dialysis patients indicate a high prevalence of adynamic bone (low bone turnover) despite PTH levels in or above the KDOQI recommended range, and this is thought to be due to overly aggressive treatment of SHPT in many patients (41). Black dialysis patients in particular may require maintenance of a higher PTH level to avoid adynamic bone (42). Although a patient may not reach PTH levels within KDOQI ranges, continued use of VDR agonists usually leads to significantly reduced PTH that remains stable over time and is accompanied by normalization of other markers of high bone turnover, such as bone-specific alkaline phosphatase and osteocalcin (30,43,44). In the clinical setting, the optimal level of PTH suppression by VDR agonists has been a matter of discussion because PTH levels are lowered and steady themselves at varying levels on the basis of individual patient response to therapy. Hypercalcemia after VDR agonist therapy may be an indication of ensuing adynamic bone and also suggests that the dose of VDR agonist should be reduced (45). In the recently released KDIGO guidelines, target ranges for PTH are set in context with the upper limit of normal per the PTH assay used (2). However, the guidelines do not make formal recommendations for PTH levels in CKD patients. Ideally, an optimal PTH level would result in a nearly normal bone formation rate (BFR). Unfortunately, PTH has only a weak correlation with BFR; therefore, despite achieving otherwise “normal” PTH levels, individuals may have low, normal, or high BFR. In general, patients with CKD stages 3 to 5 who are not on dialysis should achieve stable PTH levels near the upper limit of normal that are maintained with VDR agonist therapy while avoiding hypercalcemia and hyperphosphatemia. In dialysis patients, PTH levels should, in general, be stable and maintained at two or more times the upper limit of normal with VDR agonist therapy while avoiding hypercalcemia. The KDIGO guidelines suggest a PTH goal of two to nine times the upper limit for the assay being used in patients with CKD stage 5D (2). An elevated alkaline phosphatase level is suggestive of inadequately suppressed PTH, and therapy should be intensified to further suppress PTH.

Similar to treating other hormone-deficient diseases (e.g., hypothyroidism) (46), it is the authors' opinion that VDR agonist treatment should in general be continuous in dialysis patients so that patients can maintain normal to nearly normal levels of vitamin D hormone rather than being treated for episodic vitamin D deficiencies and/or rising PTH levels. These patients show moderate to severe 1,25-D deficiency (8) in addition to commonly having hyperphosphatemia and relative or absolute hypocalcemia. The hormonal and mineral imbalances (i.e., 1,25-D, Ca, and P) are potent inducers for PTH secretion and parathyroid proliferation. Uninterrupted use of VDR agonists can therefore remove the PTH stimulatory effect of 1,25-D deficiency and help maintain normal serum Ca, although greater use of phosphate binders may be necessary. This rationale is also consistent with the hypothesis that treatment of the 1,25-D hormonal deficiency plays a role in maintaining health via activation of the VDR in multiple organ systems, such as kidney, immunologic, and cardiovascular systems (reviewed by Andress (47)).

PTH Control by VDR Agonists and Survival

Effects of Vitamin D Receptor Agonist Treatment on Survival in Dialysis Patients.

Numerous observational studies in dialysis patients have shown improved survival after VDR agonist therapy (8,10,12,48,49). Increased risks of all-cause mortality were observed in patients with elevated mineral levels outside of KDOQI-based normal ranges (12). Hypercalcemia, hyperphosphatemia, and increased Ca × P were significantly associated with an increased risk of death. The reverse also appeared to be true; abnormally low mineral levels elevated a patient's risk of death, rounding out a U-shaped effect on mortality. In addition, the Kalantar-Zadeh et al. study (12) took into account patients who received VDR agonist therapy and demonstrated that treatment, compared with no treatment, was associated with a trend toward improved survival.

Injectable VDR agonists have been associated with a survival advantage that appears to be independent of Ca, P, and PTH levels (48). The benefit with paricalcitol was evident at essentially all baseline strata of Ca, P, and PTH. In a historic cohort study evaluating patients who changed VDR agonist therapy, those crossing over from calcitriol to paricalcitol also demonstrated a survival advantage at 2 years compared with the inverse crossover regimen (13). Cardiovascular-related mortality rates (at all basal levels of Ca, P, or PTH) were also significantly different for patients receiving paricalcitol versus patients who did not (13). Patients with advancing stages of CKD are at correlative increasing risk for cardiovascular-related events (50). Low vitamin D and 1,25-D levels correlate with increased cardiovascular disease and deaths, whereas use of VDR agonist therapy may be cardioprotective (23,48). Cardiac myocytes express the VDR (51), and vitamin D-deficient animals have significantly higher left ventricular systolic pressures compared with vitamin D-sufficient animals (52). Animals lacking signaling through the VDR, because of either knockout of the VDR (53) or 1α-vitamin D hydroxylase (54), develop left ventricular hypertrophy (LVH), whereas treatment of the latter knockout model with 1,25-D prevents LVH (54). The Dahl salt-sensitive rat develops severe hypertension, LVH, and vitamin D deficiency when maintained on a high-salt diet. Cotreatment of the Dahl salt-sensitive rats with paricalcitol has been shown to prevent LVH while not altering hypertension (55). More importantly, use of 1,25-D in dialysis patients has been shown to reduce LVH (34). Prospective cohort studies of peritoneal dialysis and hemodialysis patients with deficient or insufficient 25-D (i.e., ≤30 ng/ml) have demonstrated significantly elevated risk of cardiovascular-related mortality (8,56). This increased risk was significantly diminished in patients receiving VDR agonists (8). Collectively, these preclinical and clinical data provide a plausible mechanism by which use of VDR agonist therapy may attenuate cardiovascular-related mortality.

Effects of VDR Agonist Treatment on Survival in Patients with Stages 3 and 4 CKD.

The relationship between the use of VDR agonists with survival in CKD stages 3 and 4 patients has only recently been explored in observational studies. Use of oral VDR agonist is associated with significantly better survival, and a lower risk of initiating dialysis compared with those not prescribed treatment (9,11). As expected, the addition of vitamin D therapy suppressed PTH (9,11), and episodes of hypercalcemia and/or hyperphosphatemia were more frequent in calcitriol recipients (9,11).

Conclusions

Optimal SHPT control is important in managing the course of CKD, as well as reestablishing PTH, mineral, and vitamin D balances in the CKD patient. It is clear that vitamin D deficiency contributes to the development of SHPT in CKD patients. Depending on the stage of kidney dysfunction, repletion of both inactive (25-D) and active (1,25-D) vitamin D may be needed to adequately replace and balance physiologic levels, because signaling pathways are disrupted owing to a reduction in VDR activity. Characteristics and some of the challenges associated with vitamin D therapies for SHPT in CKD patients are presented in Table 3.

View this table:
  • View inline
  • View popup
Table 3.

Effects and challenges with vitamin D to treat SHPT in CKD patients

Guidelines for the treatment of CKD patients with SHPT were recently updated by the KDIGO working group to include a more recent perspective on SHPT treatment in CKD patients since the prior 2003 guidelines; comprehensive study details are presented by the KDIGO group (1,2). Taking the KDIGO guidance into account, as well as practical patient management experiences, several considerations are proposed to ensure optimal SHPT control in CKD patients, including early recognition of reduced eGFR, evaluation of PTH, 25-D, and/or 1,25-D starting at stage 3 CKD; optimizing VDR agonist dosing per PTH response in the individual patient; maintenance of continuous VDR agonist therapy to ensure continued PTH suppression; and vigilant monitoring of Ca and P to conform with target ranges (Table 2). The authors believe that it is a rational approach to maintain continuous VDR agonist therapy; however, there are no data to support the effectiveness of interrupted use. In addition to management of SHPT, the overall goals of these proposals are to treat what is actually a chronic hormonal deficiency and increase patient survival. Numerous observational analyses have shown beneficial effects of VDR agonists on both cardiovascular and all-cause mortality rates (8,11,22,56). These potential vitamin D-reliant cardiovascular effects and survival benefits remain to be confirmed in prospectively planned, randomized, controlled trials.

Disclosures

D.C. is a consultant to Abbott, INEOS, and Shire; is a speaker for Abbott; and participates in multicenter studies or receives research support from Abbott, Amgen, and INEOS. S.M.S. is a consultant to Abbott, Amgen, INEOS, and Shire; is a speaker for Abbott and Shire; and participates in multicenter studies or receives research support from Abbott, Amgen, INEOS, Mitsubishi, and Shire. D.C. and S.M.S. are principal investigators of a trial of comparing calcitriol to paricalcitol treatment of SHPT in stages 3 and 4 CKD.

Acknowledgments

Medical writing assistance was provided by Julie Kern, PhD, at Complete Publication Solutions LLC, in the form of drafting and revising per author direction; this assistance was funded by Abbott Laboratories.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Copyright © 2010 by the American Society of Nephrology

References

  1. ↵
    National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: S1–S201, 2003
    OpenUrlPubMed
  2. ↵
    Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl: S1–S130, 2009
  3. ↵
    1. Baker LR,
    2. Abrams L,
    3. Roe CJ,
    4. Faugere MC,
    5. Fanti P,
    6. Subayti Y,
    7. Malluche HH
    : 1,25(OH)2D3 administration in moderate renal failure: A prospective double-blind trial. Kidney Int 35: 661–669, 1989
    OpenUrlCrossRefPubMed
  4. ↵
    1. Quarles LD,
    2. Yohay DA,
    3. Carroll BA,
    4. Spritzer CE,
    5. Minda SA,
    6. Bartholomay D,
    7. Lobaugh BA
    : Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 45: 1710–1721, 1994
    OpenUrlCrossRefPubMed
  5. ↵
    1. Block GA,
    2. Klassen PS,
    3. Lazarus JM,
    4. Ofsthun N,
    5. Lowrie EG,
    6. Chertow GM
    : Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208–2218, 2004
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Kestenbaum B,
    2. Sampson JN,
    3. Rudser KD,
    4. Patterson DJ,
    5. Seliger SL,
    6. Young B,
    7. Sherrard DJ,
    8. Andress D
    : Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520–528, 2005
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Ravani P,
    2. Malberti F,
    3. Tripepi G,
    4. Pecchini P,
    5. Cutrupi S,
    6. Pizzini P,
    7. Mallamaci F,
    8. Zoccali C
    : Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 75: 88–95, 2009
    OpenUrlCrossRefPubMed
  8. ↵
    1. Wolf M,
    2. Shah A,
    3. Gutierrez O,
    4. Ankers E,
    5. Monroy M,
    6. Tamez H,
    7. Steele D,
    8. Chang Y,
    9. Camargo CA Jr..,
    10. Tonelli M,
    11. Thadhani R
    : Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72: 1004–1013, 2007
    OpenUrlCrossRefPubMed
  9. ↵
    1. Kovesdy CP,
    2. Ahmadzadeh S,
    3. Anderson JE,
    4. Kalantar-Zadeh K
    : Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 168: 397–403, 2008
    OpenUrlCrossRefPubMed
  10. ↵
    1. Naves-Diaz M,
    2. Alvarez-Hernandez D,
    3. Passlick-Deetjen J,
    4. Guinsburg A,
    5. Marelli C,
    6. Rodriguez-Puyol D,
    7. Cannata-Andia JB
    : Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 74: 1070–1078, 2008
    OpenUrlCrossRefPubMed
  11. ↵
    1. Shoben AB,
    2. Rudser KD,
    3. de Boer IH,
    4. Young B,
    5. Kestenbaum B
    : Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 19: 1613–1619, 2008
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Kalantar-Zadeh K,
    2. Kuwae N,
    3. Regidor DL,
    4. Kovesdy CP,
    5. Kilpatrick RD,
    6. Shinaberger CS,
    7. McAllister CJ,
    8. Budoff MJ,
    9. Salusky IB,
    10. Kopple JD
    : Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70: 771–780, 2006
    OpenUrlCrossRefPubMed
  13. ↵
    1. Teng M,
    2. Wolf M,
    3. Lowrie E,
    4. Ofsthun N,
    5. Lazarus JM,
    6. Thadhani R
    : Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446–456, 2003
    OpenUrlCrossRefPubMed
  14. ↵
    1. Coresh J,
    2. Selvin E,
    3. Stevens LA,
    4. Manzi J,
    5. Kusek JW,
    6. Eggers P,
    7. Van Lente F,
    8. Levey AS
    : Prevalence of chronic kidney disease in the United States. JAMA 298: 2038–2047, 2007
    OpenUrlCrossRefPubMed
  15. ↵
    1. Coresh J,
    2. Byrd-Holt D,
    3. Astor BC,
    4. Briggs JP,
    5. Eggers PW,
    6. Lacher DA,
    7. Hostetter TH
    : Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol 16: 180–188, 2005
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Levin A,
    2. Bakris GL,
    3. Molitch M,
    4. Smulders M,
    5. Tian J,
    6. Williams LA,
    7. Andress DL
    : Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 71: 31–38, 2007
    OpenUrlCrossRefPubMed
  17. ↵
    1. Craver L,
    2. Marco MP,
    3. Martinez I,
    4. Rue M,
    5. Borras M,
    6. Martin ML,
    7. Sarro F,
    8. Valdivielso JM,
    9. Fernandez E
    : Mineral metabolism parameters throughout chronic kidney disease stages 1–5–achievement of K/DOQI target ranges. Nephrol Dial Transplant 22: 1171–1176, 2007
    OpenUrlCrossRefPubMed
  18. ↵
    1. Pitts TO,
    2. Piraino BH,
    3. Mitro R,
    4. Chen TC,
    5. Segre GV,
    6. Greenberg A,
    7. Puschett JB
    : Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 67: 876–881, 1988
    OpenUrlCrossRefPubMed
  19. ↵
    1. St John A,
    2. Thomas MB,
    3. Davies CP,
    4. Mullan B,
    5. Dick I,
    6. Hutchison B,
    7. van der Schaff A,
    8. Prince RL
    : Determinants of intact parathyroid hormone and free 1,25-dihydroxyvitamin D levels in mild and moderate renal failure. Nephron 61: 422–427, 1992
    OpenUrlCrossRefPubMed
  20. ↵
    1. Holick MF
    : Vitamin D deficiency. N Engl J Med 357: 266–281, 2007
    OpenUrlCrossRefPubMed
  21. ↵
    1. Gallieni M,
    2. Kamimura S,
    3. Ahmed A,
    4. Bravo E,
    5. Delmez J,
    6. Slatopolsky E,
    7. Dusso A
    : Kinetics of monocyte 1 alpha-hydroxylase in renal failure. Am J Physiol 268: F746–F753, 1995
    OpenUrlPubMed
  22. ↵
    1. Dobnig H,
    2. Pilz S,
    3. Scharnagl H,
    4. Renner W,
    5. Seelhorst U,
    6. Wellnitz B,
    7. Kinkeldei J,
    8. Boehm BO,
    9. Weihrauch G,
    10. Maerz W
    : Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 168: 1340–1349, 2008
    OpenUrlCrossRefPubMed
  23. ↵
    1. Wang TJ,
    2. Pencina MJ,
    3. Booth SL,
    4. Jacques PF,
    5. Ingelsson E,
    6. Lanier K,
    7. Benjamin EJ,
    8. D'Agostino RB,
    9. Wolf M,
    10. Vasan RS
    : Vitamin D deficiency and risk of cardiovascular disease. Circulation 117: 503–511, 2008
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Slatopolsky E,
    2. Brown A,
    3. Dusso A
    : Pathogenesis of secondary hyperparathyroidism. Kidney Int 56: S14–S19, 1999
    OpenUrl
  25. ↵
    1. Neves KR,
    2. Graciolli FG,
    3. dos Reis LM,
    4. Graciolli RG,
    5. Neves CL,
    6. Magalhaes AO,
    7. Custodio MR,
    8. Batista DG,
    9. Jorgetti V,
    10. Moyses RM
    : Vascular calcification: Contribution of parathyroid hormone in renal failure. Kidney Int 71: 1262–1270, 2007
    OpenUrlCrossRefPubMed
  26. ↵
    1. Al-Aly Z,
    2. Qazi RA,
    3. Gonzalez EA,
    4. Zeringue A,
    5. Martin KJ
    : Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 50: 59–68, 2007
    OpenUrlCrossRefPubMed
  27. ↵
    1. Chandra P,
    2. Binongo JN,
    3. Ziegler TR,
    4. Schlanger LE,
    5. Wang W,
    6. Someren JT,
    7. Tangpricha V
    : Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: A randomized controlled pilot study. Endocr Pract 14: 10–17, 2008
    OpenUrlCrossRefPubMed
  28. ↵
    1. Zisman AL,
    2. Hristova M,
    3. Ho LT,
    4. Sprague SM
    : Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 27: 36–43, 2007
    OpenUrlCrossRefPubMed
  29. ↵
    1. Coburn JW,
    2. Maung HM,
    3. Elangovan L,
    4. Germain MJ,
    5. Lindberg JS,
    6. Sprague SM,
    7. Williams ME,
    8. Bishop CW
    : Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 43: 877–890, 2004
    OpenUrlCrossRefPubMed
  30. ↵
    1. Coyne D,
    2. Acharya M,
    3. Qiu P,
    4. Abboud H,
    5. Batlle D,
    6. Rosansky S,
    7. Fadem S,
    8. Levine B,
    9. Williams L,
    10. Andress DL,
    11. Sprague SM
    : Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 47: 263–276, 2006
    OpenUrlCrossRefPubMed
  31. ↵
    1. Mizobuchi M,
    2. Finch JL,
    3. Martin DR,
    4. Slatopolsky E
    : Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 72: 709–715, 2007
    OpenUrlCrossRefPubMed
  32. ↵
    1. Slatopolsky E,
    2. Cozzolino M,
    3. Finch JL
    : Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. Kidney Int 62: 1277–1284, 2002
    OpenUrlCrossRefPubMed
  33. ↵
    1. Andress DL,
    2. Norris KC,
    3. Coburn JW,
    4. Slatopolsky EA,
    5. Sherrard DJ
    : Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321: 274–279, 1989
    OpenUrlCrossRefPubMed
  34. ↵
    1. Park CW,
    2. Oh YS,
    3. Shin YS,
    4. Kim CM,
    5. Kim YS,
    6. Kim SY,
    7. Choi EJ,
    8. Chang YS,
    9. Bang BK
    : Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 33: 73–81, 1999
    OpenUrlCrossRefPubMed
  35. ↵
    1. Kestenbaum B,
    2. Seliger SL,
    3. Gillen DL,
    4. Wasse H,
    5. Young B,
    6. Sherrard DJ,
    7. Weiss NS,
    8. Stehman-Breen CO
    : Parathyroidectomy rates among United States dialysis patients: 1990–1999. Kidney Int 65: 282–288, 2004
    OpenUrlCrossRefPubMed
  36. ↵
    1. Gallagher JC,
    2. Bishop CW,
    3. Knutson JC,
    4. Mazess RB,
    5. DeLuca HF
    : Effects of increasing doses of 1 alpha-hydroxyvitamin D2 on calcium homeostasis in postmenopausal osteopenic women. J Bone Miner Res 9: 607–614, 1994
    OpenUrlPubMed
  37. ↵
    1. Frazao JM,
    2. Elangovan L,
    3. Maung HM,
    4. Chesney RW,
    5. Acchiardo SR,
    6. Bower JD,
    7. Kelley BJ,
    8. Rodriguez HJ,
    9. Norris KC,
    10. Robertson JA,
    11. Levine BS,
    12. Goodman WG,
    13. Gentile D,
    14. Mazess RB,
    15. Kyllo DM,
    16. Douglass LL,
    17. Bishop CW,
    18. Coburn JW
    : Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis 36: 550–561, 2000
    OpenUrlCrossRefPubMed
  38. ↵
    1. Maung HM,
    2. Elangovan L,
    3. Frazao JM,
    4. Bower JD,
    5. Kelley BJ,
    6. Acchiardo SR,
    7. Rodriguez HJ,
    8. Norris KC,
    9. Sigala JF,
    10. Rutkowski M,
    11. Robertson JA,
    12. Goodman WG,
    13. Levine BS,
    14. Chesney RW,
    15. Mazess RB,
    16. Kyllo DM,
    17. Douglass LL,
    18. Bishop CW,
    19. Coburn JW
    : Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: A sequential comparison. Am J Kidney Dis 37: 532–543, 2001
    OpenUrlCrossRefPubMed
  39. ↵
    ONE-ALPHA. In: Alphacalcidol, Johannesburg, South Africa, Adrock Ingram Critical Care (PTY) Ltd., 1988
  40. ↵
    1. Sprague SM,
    2. Llach F,
    3. Amdahl M,
    4. Taccetta C,
    5. Batlle D
    : Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63: 1483–1490, 2003
    OpenUrlCrossRefPubMed
  41. ↵
    1. Ho LT,
    2. Sprague SM
    : Renal osteodystrophy in chronic renal failure. Semin Nephrol 22: 488–493, 2002
    OpenUrlPubMed
  42. ↵
    1. Sawaya BP,
    2. Butros R,
    3. Naqvi S,
    4. Geng Z,
    5. Mawad H,
    6. Friedler R,
    7. Fanti P,
    8. Monier-Faugere MC,
    9. Malluche HH
    : Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease. Kidney Int 64: 737–742, 2003
    OpenUrlCrossRefPubMed
  43. ↵
    1. Rix M,
    2. Eskildsen P,
    3. Olgaard K
    : Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant 19: 870–876, 2004
    OpenUrlCrossRefPubMed
  44. ↵
    1. Bianchi ML,
    2. Colantonio G,
    3. Campanini F,
    4. Rossi R,
    5. Valenti G,
    6. Ortolani S,
    7. Buccianti G
    : Calcitriol and calcium carbonate therapy in early chronic renal failure. Nephrol Dial Transplant 9: 1595–1599, 1994
    OpenUrlPubMed
  45. ↵
    1. Andress DL
    : Adynamic bone in patients with chronic kidney disease. Kidney Int 2008
  46. ↵
    1. Baskin HJ,
    2. Cobin RH,
    3. Duick DS,
    4. Gharib H,
    5. Guttler RB,
    6. Kaplan MM,
    7. Segal RL
    : American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 8: 457–469, 2002
    OpenUrlPubMed
  47. ↵
    1. Andress D
    : Nonclassical aspects of differential vitamin D receptor activation: Implications for survival in patients with chronic kidney disease. Drugs 67: 1999–2012, 2007
    OpenUrlCrossRefPubMed
  48. ↵
    1. Teng M,
    2. Wolf M,
    3. Ofsthun MN,
    4. Lazarus JM,
    5. Hernan MA,
    6. Camargo CA Jr..,
    7. Thadhani R
    : Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 16: 1115–1125, 2005
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Tentori F,
    2. Hunt WC,
    3. Stidley CA,
    4. Rohrscheib MR,
    5. Bedrick EJ,
    6. Meyer KB,
    7. Johnson HK,
    8. Zager PG
    : Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 70: 1858–1865, 2006
    OpenUrlCrossRefPubMed
  50. ↵
    1. Go AS,
    2. Chertow GM,
    3. Fan D,
    4. McCulloch CE,
    5. Hsu C
    : Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–1305, 2004
    OpenUrlCrossRefPubMed
  51. ↵
    1. Walters MR,
    2. Wicker DC,
    3. Riggle PC
    : 1,25-Dihydroxyvitamin D3 receptors identified in the rat heart. J Mol Cell Cardiol 18: 67–72, 1986
    OpenUrlPubMed
  52. ↵
    1. Weishaar RE,
    2. Kim SN,
    3. Saunders DE,
    4. Simpson RU
    : Involvement of vitamin D3 with cardiovascular function. III. Effects on physical and morphological properties. Am J Physiol 258: E134–E142, 1990
    OpenUrlPubMed
  53. ↵
    1. Xiang W,
    2. Kong J,
    3. Chen S,
    4. Cao LP,
    5. Qiao G,
    6. Zheng W,
    7. Liu W,
    8. Li X,
    9. Gardner DG,
    10. Li YC
    : Cardiac hypertrophy in vitamin D receptor knockout mice: Role of systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 288: 125–132, 2005
    OpenUrlCrossRef
  54. ↵
    1. Zhou C,
    2. Lu F,
    3. Cao K,
    4. Xu D,
    5. Goltzman D,
    6. Miao D
    : Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 74: 170–179, 2008
    OpenUrlCrossRefPubMed
  55. ↵
    1. Bodyak N,
    2. Ayus JC,
    3. Achinger S,
    4. Shivalingappa V,
    5. Ke Q,
    6. Chen Y-S,
    7. Rigor DL,
    8. Stillman I,
    9. Tamez H,
    10. Kroeger PE,
    11. Wu-Wong RR,
    12. Karumanchi SA,
    13. Thadhani R,
    14. Kang PM
    : Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A 104: 16810–16815, 2007
    OpenUrlAbstract/FREE Full Text
  56. ↵
    1. Wang AY,
    2. Lam CW,
    3. Sanderson JE,
    4. Wang M,
    5. Chan IH,
    6. Lui SF,
    7. Sea MM,
    8. Woo J
    : Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: A 3-y prospective cohort study. Am J Clin Nutr 87: 1631–1638, 2008
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology
Vol. 5, Issue 3
1 Mar 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Control of Secondary Hyperparathyroidism by Vitamin D Receptor Agonists in Chronic Kidney Disease
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Control of Secondary Hyperparathyroidism by Vitamin D Receptor Agonists in Chronic Kidney Disease
Stuart M. Sprague, Daniel Coyne
CJASN Mar 2010, 5 (3) 512-518; DOI: 10.2215/CJN.03850609

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Control of Secondary Hyperparathyroidism by Vitamin D Receptor Agonists in Chronic Kidney Disease
Stuart M. Sprague, Daniel Coyne
CJASN Mar 2010, 5 (3) 512-518; DOI: 10.2215/CJN.03850609
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma
  • Anxiety in Patients Treated with Hemodialysis
  • Ultrafiltration Therapy for Heart Failure: Balancing Likely Benefits against Possible Risks
Show more Mini-Review

Cited By...

  • Secondary Hyperparathyroidism in a Patient with CKD
  • A Randomized Multicenter Trial of Paricalcitol versus Calcitriol for Secondary Hyperparathyroidism in Stages 3-4 CKD
  • Nuclear Receptors and Their Selective Pharmacologic Modulators
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire